MedPath

Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma

Phase 3
Completed
Conditions
Soft Tissue Sarcoma
Interventions
Registration Number
NCT00876031
Lead Sponsor
University Hospital Tuebingen
Brief Summary

The purpose of this study is to investigate whether the addition of oral maintenance chemotherapy with O-TIE (Etoposide, Idarubicin, Trofosfamide) for 6 months improves the event free survival (EFS) in patients with localised high-risk RMS and RMS-like Soft Tissue Sarcoma.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
195
Inclusion Criteria
  • written informed consent for registration, randomisation, data collection/transfer, and tumour material asservation available

  • pathologically (including molecular pathology) proven diagnosis of rhabdomyosarcoma (RMS) or RMS-like soft tissue sarcoma (STS) and tumour material available for pathology review

  • Rhabdomyosarcoma of the "High Risk" Group, i.e.:

    • RME, N0, M0, IRS II&III, >5 cm or >10 years in EXT, HN-PM, OTH, UG-BP
    • RME, N1, M0, any IRS-group, any size or age
    • RMA, NO, M0, any IRS-group, any size or age (exception: paratesticular RMA are not eligible) or
  • Rhabdomyosarcoma of the "Very High Risk" Group, i.e.:

    • RMA, N1, MO, IRS II&III, any size or age or
    • localised high-risk RMS-like Soft Tissue Sarcoma, i.e.:
    • EES, pPNET, UDS: any N, M0, any IRS-group, any size or age
    • SySa, any N, M0, any size or age (exception: SySa IRSI&II, not T2b, N0, M0 are not eligible)
  • no pre-existing illness preventing treatment (esp. those listed in the medicinal product information, e.g. cardiac, hepatic, metabolic, or renal dysfunction; hypersensitivity)

  • no previous malignant tumours

  • available for long term follow up through the treating centre

  • in remission (according to the CWS-2007-HR definition (see X7.1.8X)) at the time of randomisation after standard multimodal therapy e.g. according to the CWS-guidance

Exclusion Criteria
  • pregnant or lactating women
  • other medical condition precluding treatment with protocol therapy (e.g. HIV, psychiatric disorder, etc.)
  • for sexually active females and males in Arm B (O-TIE treatment): refusal to use effective contraception (e.g. oral, IUD)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
O-TIEtrofosfamide, idarubicin, etoposideoral maintenance therapy with trofosfamide, idarubicin, and etoposide
Primary Outcome Measures
NameTimeMethod
event free survival (EFS)3 years
Secondary Outcome Measures
NameTimeMethod
Overall survival5 years

Trial Locations

Locations (55)

Medical Academy

🇵🇱

Łódź, Poland

Gemeinschaftsklinikum Mayen-Koblenz

🇩🇪

Koblenz, Germany

Helios Kliniken Schwerin

🇩🇪

Schwerin, Germany

Städtisches Klinikum Karlsruhe

🇩🇪

Karlsruhe, Germany

Klinikum Minden

🇩🇪

Minden, Germany

Klinikum Oldenburg

🇩🇪

Oldenburg, Germany

Kliniken der Stadt Köln

🇩🇪

Köln, Germany

Krankenhaus München Schwabing

🇩🇪

München, Germany

Cnopf'sche Kinderklinik

🇩🇪

Nürnberg, Germany

Olgahospital

🇩🇪

Stuttgart, Germany

Collegium Medicum

🇵🇱

Bydgoszcz, Poland

Pian Medical University

🇵🇱

Szczecin, Poland

Universitätskinderklinik beider Basel

🇨🇭

Basel, Switzerland

Hopital Cantonal de Geneve

🇨🇭

Geneve, Switzerland

Dr. von Haunersches Kinderspital

🇩🇪

München, Germany

Mutterhaus der Borromäerinnen

🇩🇪

Trier, Germany

Klinikum Kassel

🇩🇪

Kassel, Germany

Asklepios Kinderklinik

🇩🇪

Sankt Augustin, Germany

Krankenhaus der Stadt Dornbirn

🇦🇹

Dornbirn, Austria

Universitätsklinik für Kinder- und Jugendheilkunde

🇦🇹

Innsbruck, Austria

Landeskrankenhaus

🇦🇹

Leoben, Austria

Landesfrauen - und Kinderklinik Linz

🇦🇹

Linz, Austria

St. Johanns Spital / Landeskrankenhaus

🇦🇹

Salzburg, Austria

St. Anna Kinderspital

🇦🇹

Wien, Austria

Universitätsklinikum

🇩🇪

Würzburg, Germany

Klinikum Augsburg

🇩🇪

Augsburg, Germany

Helios Klinikum Berlin-Buch

🇩🇪

Berlin, Germany

Charité

🇩🇪

Berlin, Germany

Universitätskinderklinik

🇩🇪

Düsseldorf, Germany

Krankenhaus Bielefeld

🇩🇪

Bielefeld, Germany

Klinikum Braunschweig

🇩🇪

Braunschweig, Germany

Prof. Hess Kinderklinik

🇩🇪

Bremen, Germany

Klinikum Chemnitz

🇩🇪

Chemnitz, Germany

Vestische Kinderklinik

🇩🇪

Datteln, Germany

Westfälisches Kinderzentrum, Klinikum Dortmund

🇩🇪

Dortmund, Germany

Medizinische Hochschule

🇩🇪

Hannover, Germany

Helios Klinikum

🇩🇪

Erfurt, Germany

Gemeinschaftskrankenhaus Herdecke

🇩🇪

Herdecke, Germany

Medical University

🇵🇱

Wroclaw, Poland

Polish-American Institute of Paediatrics Jagiellonian University Medical College

🇵🇱

Kraków, Poland

University Hospital, Dept. of Pediatrics

🇸🇪

Linköping, Sweden

Department of Surgical Oncology for Children and Youth

🇵🇱

Warszawa, Poland

Sahlgrenska University Hospital, The Queen Siliva Childrens Hospital

🇸🇪

Göteborg, Sweden

University Hospital, Dept. of Pediatric Hematology and Oncology

🇸🇪

Lund, Sweden

Karolinska University Hospital, Astrid Lindgrens Children's Hospital

🇸🇪

Stockholm, Sweden

Norrland's University Hospital, Dept. of Pediatrics

🇸🇪

Umea, Sweden

Children's University Hospital

🇸🇪

Uppsala, Sweden

Kantonsspital

🇨🇭

Aarau, Switzerland

Ospedale San Giovanni

🇨🇭

Bellinzona, Switzerland

Inselspital University hospital

🇨🇭

Bern, Switzerland

CHUV

🇨🇭

Lausanne, Switzerland

Kinderspital

🇨🇭

Luzern, Switzerland

Ostschweizer Kinderspital

🇨🇭

Sankt Gallen, Switzerland

University Children's Hospital

🇨🇭

Zurich, Switzerland

Silesian Medical Academy

🇵🇱

Katowice, Poland

© Copyright 2025. All Rights Reserved by MedPath